Revenue segments as reported by the company.

Products

Premiums

Services

Net investment income

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Benefit costs

Operating expenses

Goodwill impairment

Store impairments

Opioid litigation charges

Loss on assets held for sale

Restructuring charge

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CVS Health

Aetna is an American managed health care company, which sells traditional and consumer directed health care insurance plans and related services, such as medical, pharmaceutical, dental, behavioral health, long-term care, and disability plans. Aetna is a member of the Fortune 500.

Aetna

CVS Pharmacy is a subsidiary of the American retail and health care company CVS Health, headquartered in Woonsocket, Rhode Island. It was also known as, and originally named the Consumer Value Store and was founded in Lowell, Massachusetts, in 1963. The chain was owned by its original holding company Melville Corporation since its inception until its current parent company CVS Health was spun off into its own company in 1996. CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations (over 9,600 as of 2016) and total prescription revenue. As the retail pharmacy division of CVS Health, it ranks as the 7th largest U.S. corporation according to Fortune 500 in 2016. CVS Pharmacy's leading competitor Walgreens Boots Alliance ranked 37th.

CVS Pharmacy

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CVS Health exceeds Q4 expectations, eyes growth with Oak Street

CVS Health's strong financial performance in 2022, driven by revenue growth and exceeding EPS expectations, positions the company well for future growth.
The acquisition of Oak Street Health presents opportunities to expand into primary care and improve long-term earnings growth, despite challenges in maintaining retail performance.

CVS Health excels in Q1, eyes growth through acquisitions and innovation

CVS Health's strong financial performance, strategic acquisitions, and customer-centric initiatives position the company for sustained growth and competitive advantage.
While facing challenges in the evolving healthcare landscape, CVS Health's focus on innovation, affordability, and operational efficiency provides a solid foundation for future success.
By capitalizing on opportunities in growth, synergies, and healthcare services, CVS Health can navigate industry headwinds and drive long-term value creation for stakeholders.

CVS Health reports robust Q2 earnings, eyes growth opportunities

CVS Health's Q2 2023 performance reflects strong financial results and strategic acquisitions driving growth.
Despite challenges like higher costs and restructuring charges, the company remains confident in its ability to deliver outstanding performance.
Opportunities lie in expanding Medicaid contracts, biosimilar market establishment, and clinic openings for at-risk populations.
Overall, CVS Health's focus on cost optimization, digital sales growth, and patient engagement positions it well for future success.

CVS Health reports robust Q3 earnings and strategic growth plans

CVS Health's Q3 performance reflects strong financial results and strategic initiatives across its segments, positioning the company for sustainable growth.
While facing challenges like declining vaccine demand and contract losses, CVS Health is focused on leveraging opportunities in biosimilars and cost-saving solutions.
The company's commitment to operational excellence, innovation, and workforce investment underscores its strategic vision for becoming a leading health solutions provider.
With a clear focus on growth drivers and mitigating challenges, CVS Health is poised to capitalize on market opportunities and deliver value to shareholders.

CVS Health reports robust Q4 earnings, eyes Medicare margin recovery

CVS Health's Q4 2023 earnings call highlighted strong financial performance, a cautious stance on Medicare Advantage utilization, and a focus on transforming healthcare delivery. The company is committed to margin recovery, growth, and enhancing customer experience while addressing challenges in Medicare Advantage trends and cost pressures.

CVS Health faces Medicare Advantage challenges, focuses on margin improvement

CVS Health's Q1 2024 earnings call highlighted strong financial performance, challenges in the Medicare Advantage business, and a focus on improving margins. The company showcased strengths in the biosimilar market and Pharmacy & Consumer Wellness segment while addressing issues impacting Health Care Benefits and Services segments.

CVS Health's Q2 2024 performance reflects strong financial results, cost savings, and innovative initiatives in pharmacy services.
The company faces challenges in the Health Care Benefits segment but is actively addressing them through leadership changes and operational improvements.
Opportunities for growth include driving margin improvements, expanding digital reach, and educating stakeholders on the value delivery of PBMs.
Expectation of margin recovery in Medicare Advantage and double-digit EPS growth in 2025 highlight CVS Health's strategic focus on operational efficiencies and cost savings.

CVS Health reports robust Q3 earnings, focuses on growth strategies

CVS Health's Q3 2024 performance was marked by strong financial results, leadership changes, and segment-specific challenges and successes. The company is focused on leveraging opportunities in strategic initiatives and addressing areas for improvement to drive future growth.

Revenue

Cost of revenue

Gross profit

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CVS Health's third-quarter earnings results released Wednesday (Nov. 6) reflected the company's ongoing efforts to adapt to a changing healthcare and retail environment. As it continued to overhaul its operations in response to shifting market dynamics, including the digital transformation of healthcare, CVS faced challenges across its various business units.

CVS Health Q3 Results Reflect Struggles in Digital Health Services Amid Strategic Overhaul

CVS' third-quarter 2024 results reflect strong performance in the Health Services and Pharmacy & Consumer Wellness segments.

CVS Health Q3 Earnings & Revenues Beat, Stock Rises in Premarket

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 2% on Wednesday.

Gold Down Over 2%; CVS Health Shares Jump After Q3 Results

CVS Health Corporation (NYSE:CVS ) Q3 2024 Earnings Conference Call November 6, 2024 8:00 AM ET Company Participants David Joyner - President, Chief Executive Officer Tom Cowhey - Executive Vice President, Chief Financial Officer Prem Shah - Group President Larry McGrath - Chief Strategy Officer, Investor Relations Conference Call Participants Lisa Gill - JP Morgan Justin Lake - Wolfe Research Stephen Baxter - Wells Fargo Michael Cherny - Leerink Partners Josh Raskin - Nephron Research Elizabeth Anderson - Evercore ISI Andrew Mok - Barclays John Ransom - Raymond James Brian Tanquilut - Jefferies Operator Good morning and thank you all for attending the CVS Health third quarter 2024 earnings call and webcast. My name is Bricka and I'll be your moderator for today.

CVS Health (CVS) Q3 2024 Earnings Call Transcript

CVS Health (CVS) shares surged after the pharmacy chain and healthcare company posted better-than-expected results and new CEO David Joyner made leadership changes as he moves to shake up the struggling firm.

CVS Health Stock Rises After Company Beats Estimates

CVS Health stock (NYSE: CVS) is up over 10% on Wednesday, November 6. The broader markets as well as the health insurance stocks are rallying after the Trump victory.

Buy, Sell, Or Hold CVS Stock?

CVS Health Corp (NYSE:CVS) stock is 12% higher at $61.96 at last glance, after the pharmacy giant reported a mixed third quarter.

CVS Health Stock Surges After Mixed Quarterly Report

Although the revenue and EPS for CVS Health (CVS) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

CVS Health (CVS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Wall Street Bulls Look Optimistic About CVS Health (CVS): Should You Buy?

The move is one of the first from the new CEO, David Joyner, as he looks to repair the company.

CVS Names Former UnitedHealth Executive as Head of Aetna

CVS Health (CVS) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $2.21 per share a year ago.

CVS Health (CVS) Q3 Earnings and Revenues Surpass Estimates

CVS Health Corp (NYSE:CVS) shares jumped 10.5% pre-market in what may have been a reaction to the US presidential election results, as the drugstore and healthcare services provider reported mixed third-quarter results and failed to provide forward guidance. In the first set of numbers under new CEO David Joyner, who is thought to be leading a review of the group's options, revenues were shown to have increased 6.3% to $95.4 billion for the third quarter, better than Wall Street analysts expected.

CVS Health jumps 10% despite mixed results, as insurance stocks climb on election result

CVS's stock surges after revenue rose well above expectations, while profit missed because of a large charge premium deficiency reserves charge.

CVS beats revenue views, but profit missed due to a $1.1 billion reserve charge

UnitedHealth Group

CVS Health on Wednesday named Steve Nelson, a former UnitedHealth insurance head, to run its Aetna business, where rising medical costs in the third quarter caused the company to preannounce an earnings miss last month.

CVS taps former UnitedHealth executive to run insurance unit Aetna

CVS Health reported mixed third-quarter results as higher medical costs squeezed its bottom line. The company expects elevated medical costs to continue to pressure its performance this year, "and as a result we are not providing a formal outlook at this time," a spokesperson said.

CVS posts mixed results, holds off on guidance in Joyner's first earnings report as CEO

New CVS Health chief executive officer David Joyner promoted an internal executive, Prem Shah, as group president of the company and hired former UnitedHealth Group executive Steve Nelson to run Aetna, the nation's third largest health insurer.

New CVS Health CEO Shakes Up Management, Commits To Integrated Model

Prem Shah named Group President, CVS Health; Steve Nelson named President, Aetna WOONSOCKET, R.I. , Nov. 6, 2024 /PRNewswire/ -- CVS Health (NYSE: CVS) today announced Prem Shah will be Group President, and will continue to report to David Joyner, President and Chief Executive Officer.

CVS Health Announces Leadership Appointments

Financial Highlights Third quarter total revenues increased to $95.4 billion, up 6.3% compared to the prior year Third quarter GAAP diluted EPS of $0.07 and Adjusted EPS of $1.09 Third quarter GAAP diluted EPS and Adjusted EPS include charges to record premium deficiency reserves of approximately $1.1 billion ($0.63 per share) in the Health Care Benefits segment Generated year-to-date cash flow from operations of $7.2 billion CEO Commentary "Our integrated model accelerates our ability to uniquely do what is most important to today's health care consumers: deliver lower cost of care, a simpler experience and better outcomes. Our third quarter results reflect strong performance in the Health Services and Pharmacy & Consumer Wellness segments, and also highlight the continued need to work across our enterprise and address macro challenges to the Health Care Benefits segment.

CVS HEALTH CORPORATION REPORTS THIRD QUARTER 2024 RESULTS

GoodRx Holdings

Smaller pharmacies are accusing GoodRx and CVS of colluding to suppress generic prescription drug reimbursements. As Reuters reported Tuesday (Nov. 5), drug coupon aggregator GoodRx and a pair of pharmacy benefit managers (PBMs) — CVS's Caremark unit and Express Scripts — have all been named in at least three lawsuits by independent pharmacies.

GoodRx and CVS Sued for Suppressing Pharmacy Reimbursement

Centene

Health insurers have been getting a lot of heat surrounding the rising costs of Medicare Advantage (MA) plans. Companies like CVS Health Co. NYSE: CVS have seen their medical benefits ratio (MBR) continue to rise, forecasting 90.8%, driven by the rising costs to provide MA plans to seniors.

Medicare Advantage Costs Surge: How These 2 Insurers Are Thriving

CVS Health's David Joyner is expected to address how he will better manage rising patient costs in the Medicare business than his predecessor when he tackles his first earnings call as CEO on Wednesday, particularly after rivals have shown progress on that front in recent financial reports.

Wall Street looking for CVS to show execution plan

CVS Health (CVS) will report third-quarter earnings before the market opens Wednesday after the pharmacy and health-care provider had a rocky October that included a CEO change and layoffs, among other cost-cutting moves.

Analysts Still Bullish on CVS Ahead of Earnings Despite Recent Stock Drop

Besides Wall Street's top -and-bottom-line estimates for CVS Health (CVS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.

Curious about CVS Health (CVS) Q3 Performance? Explore Wall Street Estimates for Key Metrics

CVS Health (CVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: CVS Health (CVS) Q3 Earnings Expected to Decline

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CVS Health Corporation (NYSE: CVS) on behalf of long-term stockholders following a class action complaint that was filed against CVS on July 12, 2024 with a Class Period from May 3, 2023 to April 30, 2024. Our investigation concerns whether the board of directors of CVS have breached their fiduciary duties to the company.

CVS ALERT: Bragar Eagel & Squire, P.C. is Investigating CVS Health Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

News for CVS Health Stock (CVS)